Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.56 |
| ▸ | PAFAH1B2 | P68402 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.56 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177497 | 1.00 | MEN1 (0.56) | MEN1FAAHALDH1A1MAPTPLA2G4A | |
| SCHEMBL2783833 | 0.89 | MEN1 (0.59) | MEN1FAAHALDH1A1MAPTPLA2G4A | |
| SCHEMBL458863 | 0.88 | MEN1 (0.63) | MEN1FAAHALDH1A1MAPTPLA2G4A | |
| SCHEMBL177496 | 0.88 | MEN1 (0.63) | MEN1FAAHALDH1A1MAPTPLA2G4A | |
| SCHEMBL1887711 | 0.87 | MEN1 (0.61) | MEN1FAAHALDH1A1MAPTPLA2G4A | |
| SCHEMBL22187633 | 0.83 | ALDH1A1 (0.59) | MEN1FAAHALDH1A1MAPTPLA2G4A | |
| SCHEMBL22187634 | 0.83 | ALDH1A1 (0.59) | MEN1FAAHALDH1A1MAPTPLA2G4A | |
| SCHEMBL2783832 | 0.80 | LPAR3 (0.63) | MEN1FAAHALDH1A1MAPTPLA2G4A | |
| SCHEMBL2783835 | 0.80 | LPAR3 (0.63) | MEN1FAAHALDH1A1MAPTPLA2G4A | |
| SCHEMBL20971526 | 0.80 | LPAR3 (0.62) | MEN1FAAHALDH1A1MAPTPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190224214-A1 | HUMAN GHRELIN O-ACYLTRANSFERASE INHIBITORS | SYRACUSE UNIVERSITY (US) | 2019-07-25 | — | — | US | disclosed |
| WO-2018035079-A1 | HUMAN GHRELIN O-ACYL TRANSFERASE INHIBITORS | HOUGLAND JAMES L (US) | 2018-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190224214-A1 | HUMAN GHRELIN O-ACYLTRANSFERASE INHIBITORS | MBOAT4, LCAT, ACAT1 | MEN1 2206/4885FAAH 794/4885ALDH1A1 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.